Correlation between Clinical Characteristics and Antibody Levels in COVID-19 Convalescent Plasma Donor Candidates.
COVID-19 convalescent plasma
SARS-CoV-2
neutralizing antibody
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
12 06 2023
12 06 2023
Historique:
received:
10
05
2023
revised:
07
06
2023
accepted:
09
06
2023
medline:
29
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
COVID-19 convalescent plasma (CCP) with high neutralizing antibodies has been suggested in preventing disease progression in COVID-19. In this study, we investigated the relationship between clinical donor characteristics and neutralizing anti-SARS-CoV-2 antibodies in CCP donors. COVID-19 convalescent plasma donors were included into the study. Clinical parameters were recorded and anti-SARS-CoV-2 antibody levels (Spike Trimer, Receptor Binding Domain (RBD), S1, S2 and nucleocapsid protein) as well as ACE2 binding inhibition were measured. An ACE2 binding inhibition < 20% was defined as an inadequate neutralization capacity. Univariate and multivariable logistic regression analysis was used to detect the predictors of inadequate neutralization capacity. Ninety-one CCP donors (56 female; 61%) were analyzed. A robust correlation between all SARS-CoV-2 IgG antibodies and ACE2 binding inhibition, as well as a positive correlation between donor age, body mass index, and a negative correlation between time since symptom onset and antibody levels were found. We identified time since symptom onset, normal body mass index (BMI), and the absence of high fever as independent predictors of inadequate neutralization capacity. Gender, duration of symptoms, and number of symptoms were not associated with SARS-CoV-2 IgG antibody levels or neutralization. Neutralizing capacity was correlated with SARS-CoV-2 IgG antibodies and associated with time since symptom onset, BMI, and fever. These clinical parameters can be easily incorporated into the preselection of CCP donors.
Identifiants
pubmed: 37376656
pii: v15061357
doi: 10.3390/v15061357
pmc: PMC10301943
pii:
doi:
Substances chimiques
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Spike Glycoprotein, Coronavirus
0
Antibodies, Viral
0
Antibodies, Neutralizing
0
Immunoglobulin G
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Front Med (Lausanne). 2021 Jun 07;8:684151
pubmed: 34164419
Front Public Health. 2021 Sep 27;9:732787
pubmed: 34646805
N Engl J Med. 2022 May 5;386(18):1700-1711
pubmed: 35353960
Transfusion. 2021 Mar;61(3):830-838
pubmed: 33231325
Obesity (Silver Spring). 2016 Mar;24(3):615-25
pubmed: 26857091
Nat Commun. 2021 Feb 19;12(1):1152
pubmed: 33608538
Transfus Med Hemother. 2021 May;48(3):137-147
pubmed: 34177417
Nat Rev Immunol. 2015 Jun;15(6):335-49
pubmed: 25976513
Front Immunol. 2023 Mar 22;14:1106664
pubmed: 37033936
J Clin Invest. 2022 Dec 15;132(24):
pubmed: 36326824
J Clin Invest. 2020 Jun 1;130(6):2757-2765
pubmed: 32254064
PLoS Med. 2021 Dec 20;18(12):e1003872
pubmed: 34928960
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6
pubmed: 15616839
Sci Rep. 2022 May 3;12(1):7168
pubmed: 35505068
JAMA Intern Med. 2020 Oct 1;180(10):1356-1362
pubmed: 32808970
N Engl J Med. 2021 Mar 18;384(11):1015-1027
pubmed: 33523609
J Immunol. 2022 Apr 1;208(7):1711-1718
pubmed: 35321882
Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100763
pubmed: 33997476
Viruses. 2021 Aug 11;13(8):
pubmed: 34452459
Transfusion. 2010 Jun;50(6):1384-98
pubmed: 20158681
Cell Mol Immunol. 2021 Apr;18(4):936-944
pubmed: 33139905
PLoS One. 2021 Mar 24;16(3):e0245424
pubmed: 33760825
Ann Intern Med. 2022 Sep;175(9):1310-1321
pubmed: 35969859
J Clin Invest. 2021 Feb 1;131(3):
pubmed: 33320842
J Intern Med. 2021 Apr;289(4):559-573
pubmed: 33034095
Front Immunol. 2023 Mar 15;14:1146702
pubmed: 37056776
J Clin Invest. 2021 Oct 15;131(20):
pubmed: 34464358
Obesity (Silver Spring). 2021 Sep;29(9):1547-1553
pubmed: 33945220
J Clin Invest. 2020 Nov 2;130(11):6141-6150
pubmed: 32764200
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Front Immunol. 2021 Jan 29;11:628971
pubmed: 33584731
PLoS One. 2020 Dec 31;15(12):e0244126
pubmed: 33382764
Nat Cancer. 2023 Jan;4(1):96-107
pubmed: 36581734
Thromb Res. 2022 Aug;216:120-124
pubmed: 35810548
Hamostaseologie. 2022 Oct;42(S 01):S14-S23
pubmed: 36288732